MARKET WIREYahoo Finance Australia • 14h ago
Celcuity Inc. (CELC) stock price, news, quote and historyYahoo Finance Australia report covering Celcuity Inc. (CELC) market action, institutional positioning, and fundamental catalysts.
Why CELC Stock slipped -0.24% Today — RQD Quant Desk Flash
$69.13 -0.24% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $68.97
Celcuity Inc. (CELC) carries a Roarable Rating of E (Strong Sell) with 32/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $3.39B
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on CELC Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is CELC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, Celcuity Inc. (NASDAQ: CELC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $69.13 (-0.24% 1D, market cap $3.39B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CELC ranks #767 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does CELC compare to CDNA and ACHC in the Health Care sector?
▼
Within the Health Care sector (Medical Specialities), CELC carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CDNA (CareDx Inc.) holds a C+ grade (69/100 RQD, P/E N/A, ROIC -8.2%, cap $3.70B) and ACHC (Acadia Healthcare Company Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -24.8%, cap $2.74B). Among the 5-stock peer group, VCYT leads on earnings multiple (63.2x) while VCYT leads on capital efficiency (4.6% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for CELC?
▼
Per CELC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001603454), Celcuity Inc. generated $0 in revenue, -$177.0M in net income, and -$153.5M in free cash flow against $466.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $68.97 (-0.23%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (32/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.2% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Each axis scored 0–20
12M PRICE TARGET CONE-11.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CELC)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (32/100 Composite)
🔍 WHY CELC SCORES 32/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (31% of score)
Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▲ #2 Bullish Driver: Macro Regime Fit+7/20 pts (22% of score)
FRED Regime × Technicals: 16% of 52W Range • RSI-14 at 49.7 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$65.85-13.3% Next Q
24
Q2 (-2Q)Grade E$57.12+15.2% Next Q
27
Q3 (-1Q)Grade E$65.80+5.1% Next Q
29
CurrentGrade E$69.13-9.2% Hist 90D α
32
Trajectory: E (24) → E (32)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a CELC Turnaround Squeeze
While CELC currently carries a cautious 32/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($77.18) and Max Pain ($72.59) forces dealer call-delta covering toward $158.57.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $CELC• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CELC Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why CELC Stock slipped -0.24% Today — RQD Quant Desk Flash
Celcuity Inc. (CELC) slipped -0.24% to $69.13, trading at 16% of its 52-week range ($53.54 – $151.02). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 16% of its 52-week range ($53.54 – $151.02) with RSI-14 at 49.7 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $69.13 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live CELC Headlines & Catalysts
MARKET WIREInvesting.com • 17h ago
how InvestingPro’s Fair Value flagged Celcuity’s 52% decline By Investing.comInvesting.com report covering Celcuity Inc. (CELC) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 20h ago
Celcuity: Stronger Clinical Evidence, Much Lower Valuation (NASDAQ:CELC)Seeking Alpha report covering Celcuity Inc. (CELC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 23h ago
Celcuity (CELC) Stock May Be Hard To Value On Book ValueYahoo Finance report covering Celcuity Inc. (CELC) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESimply Wall St • 1d ago
How Drug Launch Coverage Will Impact Celcuity Stock (CELC) InvestorsSimply Wall St report covering Celcuity Inc. (CELC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 1d ago
Celcuity (CELC) Short Interest & Short Float | Updated Oct 2026MarketBeat report covering Celcuity Inc. (CELC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
A late-breaking breast cancer trial update will join three other presentations at a European cancer meeting.Stock Titan report covering Celcuity Inc. (CELC) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo Finance • 1d ago
Celcuity (CELC) Is Down 17.3% After REVTORPYK US Launch And sNDA Filing News EventYahoo Finance report covering Celcuity Inc. (CELC) market action, institutional positioning, and fundamental catalysts.
CATALYSTSeekingAlpha • 3d ago
Celcuity: Stronger Clinical Evidence, Much Lower ValuationCelcuity Inc. retains a Buy rating after REVTORPYK's FDA approval and robust mutant data, despite a significant share price drop. Learn more about CELC stock here.
MARKET WIREYahoo • 4d ago
Celcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference CallMINNEAPOLIS, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CELC)
- ✓Walkthrough of CELC's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
CELC // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -52.32%▼ DESCENDING CHANNEL
2026-11-02O $69.46H $69.46L $69.13C $69.13VOL 820.7K
RES: $77.74SUP: $46.17SMA50: $77.18SMA200: $100.5
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
CELC Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on CELC today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for CELC. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CELC today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CELC)
Health Care Rank #767 of 1016
⚔️ CDNA vs CELC Full Matrix →
1. Head-to-Head Health Care Peer Comparison (CELC vs. CDNA, ACHC, VCYT, CLOV)
Industry: Medical Specialities (41 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Celcuity Inc. (CELC) ranks #767 by composite RQD confidence (32/100, grade E) and #196 by equity capitalization ($3.39B). Within this direct 5-issuer industry benchmark cohort, VCYT leads on earnings valuation at 63.2x trailing P/E, while VCYT leads on capital efficiency and profitability with 4.6% ROIC and 70.1% gross margin. VCYT currently holds the highest overall quantitative score in the immediate peer group at 74/100 (B) compared with CELC at 32/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| CELC
ACTIVE
Celcuity Inc. | E | 32/100 | — | — | -35.0% | -0.24% | $3.39B | Benchmark Subject |
| CDNA CareDx Inc. | C+ | 69/100 | — | — | -8.2% | +22.22% | $3.70B | /cdna-vs-celc → |
| ACHC Acadia Healthcare Company Inc. | D- | 37/100 | — | — | -24.8% | +1.70% | $2.74B | /achc-vs-celc → |
| VCYT Veracyte Inc. | B | 74/100 | 63.2x | 70.1% | 4.6% | -4.14% | $4.19B | /vcyt-vs-celc → |
| CLOV Clover Health Investments Corp. (Class A) | D- | 38/100 | — | — | -29.3% | -2.62% | $2.43B | /clov-vs-celc → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001603454In its most recent audited fiscal period (FY2025, filed 2025-12-31), Celcuity Inc. (CELC) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$177.0M, operating cash flow of -$153.3M, and free cash flow of -$153.5M (-83.4% YoY). On the balance sheet, CELC closed FY2025 with $466.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$177.0M | -$153.3M | -$153.5M | $466.6M | — |
| FY2024 (FY) | 2024-12-31 | $0 | -$111.8M | -$83.5M | -$83.7M | $245.1M | — |
| FY2023 (FY) | 2023-12-31 | $0 | -$63.8M | -$53.8M | -$53.8M | — | — |
3. CELC Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs CELC stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, Celcuity Inc. (NASDAQ: CELC) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 32/100 at a spot price of $69.13 (-0.24% 1D, market cap $3.39B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, CELC ranks #767 in composite RQD confidence.
How does CELC compare to CDNA and ACHC in the Health Care sector?
Within the Health Care sector (Medical Specialities), CELC carries a Roarable E (32/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, CDNA (CareDx Inc.) holds a C+ grade (69/100 RQD, P/E N/A, ROIC -8.2%, cap $3.70B) and ACHC (Acadia Healthcare Company Inc.) posts a D- grade (37/100 RQD, P/E N/A, ROIC -24.8%, cap $2.74B). Among the 5-stock peer group, VCYT leads on earnings multiple (63.2x) while VCYT leads on capital efficiency (4.6% ROIC).
What are the biggest fundamental strengths and SEC risk factors for CELC?
Per CELC's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001603454), Celcuity Inc. generated $0 in revenue, -$177.0M in net income, and -$153.5M in free cash flow against $466.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is CELC trading relative to its 50-day, 200-day, and 52-week technical levels?
CELC last traded at $69.13 (-0.24% on volume of 700,119 shares), positioning the stock -10.43% below its 50-day simple moving average ($77.18) and -31.18% below its 200-day simple moving average ($100.45). Across its 52-week range of $53.54 to $151.02, CELC sits at the 16.0% percentile with a 14-day RSI of 49.7 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($60.49 to $77.77).
CELC Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is CELC stock moving today?
Why CELC Stock slipped -0.24% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 32/100 (E)
✓ STAGE-C NUMBER FIREWALL VERIFIED
CELC — Celcuity Inc.: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:23:29Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, CELC scores 32 out of 100 with a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are: Fundamental Cash Engine at 6/20 (ROIC -35%; FCF yield -4.53%); Whale 13F Flow at 6/20 (institutional accumulation and options positioning); Insider Conviction at 3/20 (SEC Form 4 and Congressional PTR cluster flow); Macro Regime Fit at 7/20 (Beta 1.0; sector sensitivity); and Forensic Balance Sheet at 10/20 (Altman Z 2.5; Piotroski F 2/9; Debt/Equity 0.5).
Taken together, the lowest-scoring pillars point to weak cash generation and weak insider conviction, the two areas most directly tied to whether the business can self-fund and whether those closest to it are signaling confidence. The highest-scoring pillar, the balance sheet, is only moderate, with a Piotroski F-Score of 2 out of 9 indicating limited financial-strength signals. Per the SEC financials, the company reported negative operating income and negative free cash flow in each of the three listed fiscal years, and the reported cash balance rose from $22.5M to $165.7M over FY 2024 to FY 2025 while FCF was negative in both years. For a prospective investor, the upside case rests on the company's ability to convert its cash position and clinical activity into a sustainable cash engine; the valuation tradeoff is that the market cap of $3.39B is not supported by reported earnings or cash flow in the source data, and the Beta of 1.0 means the stock is expected to move with the broader market rather than independently. This is an analytical framing, not personalized financial advice.
Business
Celcuity Inc. (CELC) is a NASDAQ-listed issuer in the Health Care sector and the Medical Specialities industry, per the profile. The source data does not describe the company's products, customers, or revenue model. The reported revenue in every listed period is $0.0M, per the SEC financials. Not available in source data for the specific product or customer base.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $0.0M | $-172.2M | $-177.0M | N/A | $-153.5M | $165.7M | N/A |
| FY 2024 | $0.0M | $-113.3M | $-111.8M | N/A | $-83.7M | $22.5M | N/A |
| FY 2023 | $0.0M | $-66.2M | $-63.8M | N/A | $-53.8M | N/A | N/A |
Per the SEC financials, reported revenue was $0.0M in each period and operating losses widened from $-66.2M in FY 2023 to $-172.2M in FY 2025. Gross, operating, and net margins are each listed as 0% in the market data, and ROIC is -35%. The Altman Z-Score is 2.5 and the Piotroski F-Score is 2 out of 9, per the Roarable RQD rating. Debt/Equity is listed as 0.5, while the debt line in the SEC financials is N/A for all periods.
Open Questions
- What products or indications does CELC commercialize, and what is the revenue model behind the reported $0.0M revenue?
- What drove the increase in cash from $22.5M to $165.7M between FY 2024 and FY 2025, and how is the company funding negative free cash flow?
- What is the nature of the debt position, given that debt is listed as N/A while Debt/Equity is 0.5?
- What specific catalysts are referenced in the recent news items, and what is their timing?
- What is the reason for the difference between a 52-week low of $53.54 and a high of $151.02 relative to the current price of $69.3?
CELC Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for Celcuity Inc. (CELC) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance Australia • 14h ago
Celcuity Inc. (CELC) stock price, news, quote and history Yahoo Finance Australia report covering Celcuity Inc. (CELC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Investing.com • 17h ago
how InvestingPro’s Fair Value flagged Celcuity’s 52% decline By Investing.com Investing.com report covering Celcuity Inc. (CELC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 20h ago
Celcuity: Stronger Clinical Evidence, Much Lower Valuation (NASDAQ:CELC) Seeking Alpha report covering Celcuity Inc. (CELC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 23h ago
Celcuity (CELC) Stock May Be Hard To Value On Book Value Yahoo Finance report covering Celcuity Inc. (CELC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Simply Wall St • 1d ago
How Drug Launch Coverage Will Impact Celcuity Stock (CELC) Investors Simply Wall St report covering Celcuity Inc. (CELC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 1d ago
Celcuity (CELC) Short Interest & Short Float | Updated Oct 2026 MarketBeat report covering Celcuity Inc. (CELC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
A late-breaking breast cancer trial update will join three other presentations at a European cancer meeting. Stock Titan report covering Celcuity Inc. (CELC) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Yahoo Finance • 1d ago
Celcuity (CELC) Is Down 17.3% After REVTORPYK US Launch And sNDA Filing News Event Yahoo Finance report covering Celcuity Inc. (CELC) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
CELC Bull vs. Bear Conversation Board — What's Your Call at $69.13?
🐂 33% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CELC 🐻 67% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk 🐻 BEARISH
🎯 Target: $60.98 (-12.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is CELC (E • RQD 32/100) a Buy at $69.30?
Welcome to the CELC (Celcuity Inc.) Roar Pit. Current RQD Composite is 32/100 (Roarable Strong Sell — Forensic Risk / Avoid) in Medical Specialities. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
SK SkepticalCFA Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $51.98 (-25.0%)
Spot @ $69.30 Pump the brakes on CELC — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on CELC, but look at what you are paying: current EV/EBITDA multiples with tightening sector spreads. Unless Celcuity Inc. expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
SI SiliconVal_Bull Verified K Arena Trader 🐂 BULLISH
🎯 Target: $88.70 (+28.0%)
Spot @ $69.30 CELC cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on CELC, the market is fixating on short-term headline noise in Medical Specialities and ignoring the balance sheet and cash flow trajectory. At $69.30 (52-wk range $53.54 - $151.02), any beat on forward guidance forces shorts and underweight funds to chase.